# EDGAR Filing Document

**Accession Number:** 0002107059
**File Stem:** 0001104659-26-039490
**Filing Date:** 2026-4
**Character Count:** 25596
**Document Hash:** 170574920ca90a6c62414a0933d80884
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-039490.hdr.sgml**: 20260403

**ACCESSION NUMBER**: 0001104659-26-039490

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260403

**DATE AS OF CHANGE**: 20260403

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Celularity Inc
- **CENTRAL INDEX KEY:** 0001752828
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831702591
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91021
- **FILM NUMBER:** 26837163

**BUSINESS ADDRESS:**
- **STREET 1:** 170 PARK AVE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932
- **BUSINESS PHONE:** (908) 768-2170

**MAIL ADDRESS:**
- **STREET 1:** 170 PARK AVE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GX Acquisition Corp.
- **DATE OF NAME CHANGE:** 20180912
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Philip & Daniele Barach Family Trust
- **CENTRAL INDEX KEY:** 0002107059

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 434 SURFVIEW DRIVE
- **CITY:** PACIFIC PALISADES
- **STATE:** CA
- **ZIP:** 90272
- **BUSINESS PHONE:** (818) 694-0182

**MAIL ADDRESS:**
- **STREET 1:** 434 SURFVIEW DRIVE
- **CITY:** PACIFIC PALISADES
- **STATE:** CA
- **ZIP:** 90272

## Exhibit 99.1

**EXHIBIT 1**

**JOINT FILING AGREEMENT**

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that the Schedule 13D to which this Joint Filing Agreement is being filed as an exhibit shall be a joint statement filed on behalf of each of the undersigned.

---

| | | |
|:---|:---|:---|
| Date: April 2, 2026 |  |  |
|  | **PHILIP & DANIELE BARACH FAMILY TRUST** | **PHILIP & DANIELE BARACH FAMILY TRUST** |
|  | By: | */s/ Philip A. Barach* |
|  | Philip A. Barach, as Trustee of the Philip & Daniele Barach Family Trust | Philip A. Barach, as Trustee of the Philip & Daniele Barach Family Trust |
|  |  | /s/ Philip A. Barach |
|  |  | &nbsp;&nbsp;&nbsp;Philip A. Barach |
|  |  | /s/ Daniele Barach |
|  |  | &nbsp;&nbsp;&nbsp;Daniele Barach |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Celularity Inc.**

*(Name of Issuer)*

**Class A Common Stock, Par Value $0.0001 Per Share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Philip & Daniele Barach Family**<br>Philip A. Barach, Daniele Barach<br>434 Surfview Drive<br>Pacific Palisades CA 90272<br>(818) 694-0182

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/19/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**PHILP & DANIELE BARACH FAMILY TRUST** | Name of reporting person<br>**PHILP & DANIELE BARACH FAMILY TRUST** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CALIFORNIA** | Citizenship or place of organization<br>**CALIFORNIA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3012048.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3012048.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3012048.00** | Aggregate amount beneficially owned by each reporting person<br>**3012048.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.56%** | Percent of class represented by amount in Row (11)<br>**9.56%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**PHILIP A. BARACH** | Name of reporting person<br>**PHILIP A. BARACH** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CALIFORNIA** | Citizenship or place of organization<br>**CALIFORNIA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3012048.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3012048.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3012048.00** | Aggregate amount beneficially owned by each reporting person<br>**3012048.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.56%** | Percent of class represented by amount in Row (11)<br>**9.56%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**DANIELE BARACH** | Name of reporting person<br>**DANIELE BARACH** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CALIFORNIA** | Citizenship or place of organization<br>**CALIFORNIA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3012048.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3012048.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3012048.00** | Aggregate amount beneficially owned by each reporting person<br>**3012048.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.56%** | Percent of class represented by amount in Row (11)<br>**9.56%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class A Common Stock, Par Value $0.0001 Per Share

**(b) Name of Issuer:**
Celularity Inc.

**(c) Address of Issuer's Principal Executive Offices:**
170 Park Ave, Florham Park, NJ, 07932

**Item 4. Purpose of Transaction**

The Reporting Persons expect to evaluate on an ongoing basis the Issuer's financial condition and prospects and their interest in, and intentions with respect to, the Issuer and their investment in the securities of the Issuer, which review may be based on various factors, including the Issuer's business and financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's securities in particular, as well as other developments and other investment opportunities, which, if effected, could result in, among other things, any of the matters identified in Items 4(a)-(j) of Schedule 13D. Accordingly, the Reporting Persons reserve the right to change their intentions and develop plans or proposals at any time, as they deem appropriate. In particular, the Reporting Persons may at any time and from time to time, (i) in the open market, in privately negotiated transactions or otherwise, acquire additional Class A Common Stock or other securities of the Issuer, including acquisitions from affiliates of the Reporting Persons; (ii) dispose or transfer of all or a portion of the securities of the Issuer, including the Class A Common Stock, that the Reporting Persons now own or may hereafter acquire to any person or entity, including dispositions to affiliates of the Reporting Persons; (iii) enter into derivative transactions with institutional counterparties with respect to the Issuer's securities; (iv) cause or seek to cause the Issuer or any of its subsidiaries to acquire all or a portion of another person's assets or business, including acquisitions from affiliates of the Reporting Persons; (v) cause or seek to cause the Issuer or any of its subsidiaries to enter into one or more acquisitions, business combinations or mergers or to sell, transfer or otherwise dispose of all or any portion of its assets or business to any person or entity, including acquisitions, business combinations, mergers, sales, transfers and other dispositions with or to affiliates of the Reporting Persons; (vi) restructure the Issuer's or any of its subsidiaries' capitalization, indebtedness or holding company arrangements; (vii) make personnel changes to the present management of the Issuer deemed necessary or desirable; (viii) change the identity of the directors of the Issuer; (ix) make or propose any other material change in the Issuer's or any of its subsidiaries' corporate structure or business; or (x) engage in communications with one or more stockholders, officers or directors of the Issuer and other persons regarding any of the matters described in clauses (i) through (ix) above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information contained on the cover pages to this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 is incorporated herein by reference. Each of the Reporting Persons beneficially owns 3,012,048 shares of Class A Common Stock, which number assumes the issuance of Additional Convertible Notes in the aggregate principal amount of $2,000,000 and conversion of the entire $5,000,000 in aggregate principal amount of all Convertible Notes into 3,012,048 shares of Class A Common Stock at a conversion price of $1.66 per share.  The shares of Class A Common Stock beneficially owned by the Reporting Persons represents 9.56% of the shares of Class A Common Stock issued and outstanding, which calculation is based on 28,478,880 shares of Class A Common Stock of the Company issued and outstanding as of December 19, 2025, which was the date of the closing of the Financing.   Each of Mr. Barach and Ms. Barach disclaims beneficial ownership of the shares of Class A Common Stock owned by the Trust, except to the extent of their pecuniary interest therein.

**(b)**
The information contained on the cover pages to this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 is incorporated herein by reference.  None of the Reporting Persons has the sole power to vote or to direct the vote, or the sole power to dispose or to direct the disposition of, any of the shares of Class A Common Stock owned by such Reporting Person.  Each Reporting Person shares with the other Reporting Persons the power to vote or to direct the vote, or the power to dispose or to direct the disposition of, all 3,012,048 shares of Class A Common Stock owned by the Reporting Persons.

**(c)**
No members of the Trust had any transactions in the Class A Common Stock (or securities convertible into or exercisable for shares of Class A Common Stock) during the past 60 days, except as described and referenced in Item 3 of this Schedule 13D.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

On December 19, 2025 (the "Effective Date"), the Company entered into a series of agreements relating to the Financing with the Trust.

Senior Secured Notes Financing

On the Effective Date, the Company entered into a Senior Securities Purchase Agreement (the "Senior Securities Purchase Agreement") with the Trust pursuant to which the Company issued the Trust the Senior Note in the principal amount of $7,000,000 and a warrant to purchase up to 2,448,917 shares of Class A Common Stock (the "Senior Note Warrant"). Pursuant to the Senior Securities Purchase Agreement, the Company may sell up to an aggregate of $8,400,000 in principal amount of Senior Notes before June 19, 2026 to the Trust and one or more Participation Purchasers (as defined in the Senior Securities Purchase Agreement and, together with the Trust, the "Senior Note Purchasers").

The Senior Note accrues interest at a rate of 4% per annum (increasing to 12% per annum upon the occurrence of an Event of Default (as defined in the Senior Note)) and matures upon the earlier of (i) April 30, 2026 and (ii) the consummation by the Company a debt or equity financing, asset sale, licensing agreement or similar strategic transaction resulting in gross proceeds equal to or greater than the then-outstanding principal amount of the Senior Notes. Prior to the maturity date of the Senior Note, the Company may, at its election, redeem the principal amount of the Senior Note together with interest accrued therein for cash in an amount equal to the Optional Redemption Amount (as defined in the Senior Note). The Senior Note ranks pari passu in right of payment and in all other respects to any other Senior Notes and Convertible Notes.

The Senior Note Warrant is exercisable commencing on June 19, 2026 and terminates on December 19, 2030. The Senior Note Warrant is exercisable for shares of the Company's Class A Common Stock at a price of $2.00 per share, subject to adjustment set forth therein.

Pursuant to the Senior Securities Purchase Agreement, until such date that no Senior Notes are outstanding, if the Company enters into any public or private offering of its securities (including securities convertible into shares of its Class A Common Stock) with any individual or entity (an "Other Investor") that has the effect of establishing rights or otherwise benefiting such Other Investor in a manner more favorable to such Other Investor than the rights and benefits established in favor of the Senior Note Purchasers, at each Senior Note Purchaser's option, such more favorable terms shall become a part of the Transaction Documents (as defined in the Senior Securities Purchase Agreement). Furthermore, if the Company conducts a Subsequent Financing (as defined in the Senior Securities Purchase Agreement), the Senior Note Purchasers shall have the right to participate in up to an amount of the Subsequent Financing equal to their respective subscription amounts on the same terms, conditions and price provided for in the Subsequent Financing.

In connection with the issuance of the Senior Note, on the Effective Date, the Company entered into a security agreement (the "Senior Note Security Agreement") with the Agent (as defined in the Senior Note Security Agreement) and Secured Party (as defined in the Senior Note Security Agreement) pursuant to which the Company granted the Trust a first-priority security interest over substantially all of the assets of the Company, subject to certain customary exclusions and priority agreements.

Convertible Notes Financing

On the Effective Date, the Company also entered into the Convertible Note Purchase Agreement with the Trust pursuant to which the Company issued to the Trust the Convertible Note in the principal amount of $3,000,000 and a warrant to purchase up to 1,258,740 shares of the Company's Class A Common Stock (the "Convertible Note Warrant"). Pursuant to the Convertible Note Purchase Agreement, the Trust may purchase up to an aggregate of $2,000,000 of Additional Convertible Notes, which right shall expire upon the earlier of (i) six months following the Effective Date and (ii) the occurrence of an Event of Default (as defined in the Convertible Note). Pursuant to the Convertible Note Purchase Agreement, the Company may sell up to an aggregate of $6,200,000 in principal amount of Convertible Notes before June 19, 2026 to the Trust and one or more Participation Purchasers (as defined in the Convertible Note Purchase Agreement and, together with the Trust, the "Convertible Note Purchasers").

The Convertible Note accrues interest at 8% per annum (increasing to 12% per annum upon the occurrence of an Event of Default (as defined in the Convertible Note)), payable in kind, and matures on December 31, 2026. Any additional Convertible Notes issued pursuant to Convertible Note Purchase Agreement shall mature on such date that is one year from the date such notes are issued. The Convertible Note is convertible at the option of the holder into shares of Class A Common Stock at a conversion price of $1.66 per share, subject to adjustment and limitations set forth therein (the "Conversion Price"). Upon the consummation of a Qualified Financing (as defined in the Convertible Note), the Company may elect to convert up to 100% of the then outstanding principal amount of the Convertible Note together with interest accrued thereon into such number of shares of the Company's Class A common stock as is determined by dividing (i) 100% of the then outstanding principal amount of the Convertible Note together with interest accrued thereon by (ii) the lowest price per share used in the Qualified Financing at which shares of Class A Common Stock or Common Stock Equivalents (as defined in the Convertible Note Purchase Agreement) are sold. Prior to the maturity date of the Convertible Notes, the Company may, at its election, redeem the principal amount of the Convertible Notes together with interest accrued therein for cash in an amount equal to the Optional Redemption Amount (as defined in the Convertible Note). Pursuant to the Convertible Note, if the Company issues additional shares of Class A Common Stock without consideration or for a consideration per share less than the Conversion Price, then the Conversion Price shall be reduced as set forth in the Convertible Note, subject to customary exceptions. The Convertible Note ranks pari passu in right of payment and in all other respects to any other Senior Notes and Convertible Notes.

The Convertible Note Warrant is exercisable commencing on June 19, 2026 and terminates on December 19, 2030. The Convertible Note Warrant is exercisable for shares of the Company's Class A common stock at a price of $2.00 per share, subject to adjustment set forth therein.

Pursuant to the Convertible Note Purchase Agreement, until such date that no Convertible Notes are outstanding, if the Company enters into any public or private offering of its securities (including securities convertible into shares of its Class A Common Stock) with any Other Investor that has the effect of establishing rights or otherwise benefiting such Other Investor in a manner more favorable to such Other Investor than the rights and benefits established in favor of the Convertible Note Purchasers, at each Convertible Note Purchaser's option, such more favorable terms shall become a part of the Transaction Documents (as defined in the Convertible Note Purchase Agreement). Furthermore, if the Company conducts a Subsequent Financing (as defined in the Convertible Note Purchase Agreement), the Convertible Note Purchasers shall have the right to participate in up to an amount of the Subsequent Financing equal to their respective subscription amounts on the same terms, conditions and price provided for in the Subsequent Financing.

In connection with the Convertible Note Financing, on the Effective Date, the Company entered into a security agreement (the "Convertible Note Security Agreement") with the Agent (as defined in the Convertible Note Security Agreement) and Secured Party (as defined in the Convertible Note Security Agreement) pursuant to which the Company granted the Trust a first-priority security interest over certain of the proceeds from a Qualified Financing.

Registration Rights Agreement

In connection with the Financing, on the Effective Date, the Company entered into a registration rights agreement (the "Registration Rights Agreement") with the Trust pursuant to which the Company shall prepare and file with the Securities and Exchange Commission (the "SEC" or the "Commission") a registration statement covering the Registrable Securities (as defined in the  Registration Rights Agreement) on or prior to the date that is 45 calendar days following the Effective Date. The Company shall use its best efforts to cause the registration statement covering the Registrable Securities to be declared effective as promptly as practicable after the filing thereof, but in any event no later the 90th calendar day following the Effective Date (or in the event of a full review by the SEC, the 120th calendar day following the Effective Date).

Board Observer Agreement

In connection with the Financing, on the Effective Date, the Company entered into a board observer rights agreement (the "Board Observer Rights Agreement") with the Trust granting the Trust the right to designate one non-voting observer to attend meetings of the Company's Board of Directors. The initial observer will be Philip Barach.  The Board Observer Rights Agreement shall terminate on the earliest to occur of: (i) the date the Trust and its affiliates collectively beneficially own less than 5% of the Company's outstanding Class A Common Stock on an as-converted, as-exercised basis; (ii) the consummation of a Change of Control (as defined in the Board Observer Rights Agreement); and (iii) the termination of the Board Observer Rights Agreement pursuant to its terms.

The foregoing descriptions of the Senior Note Warrant, the Senior Securities Purchase Agreement, the Senior Note, the Senior Note Security Agreement, the Convertible Note Warrant, the Convertible Note Purchase Agreement, the Convertible Note, the Convertible Note Security Agreement, the Registration Rights Agreement and the Board Observer Agreement are not complete and are qualified in their entirety by reference to the full text of the forms of such agreements and instruments, copies of which are filed as Exhibits to this Schedule 13D and are incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** PHILP & DANIELE BARACH FAMILY TRUST

**Signature:** /s/ Philip A. Barach

**Name/Title:** Philip A. Barach, Trustee of the Trust

**Date:** 04/02/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** PHILIP A. BARACH

**Signature:** /s/ Philip A. Barach

**Name/Title:** Philip A. Barach

**Date:** 04/02/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** DANIELE BARACH

**Signature:** /s/ Daniele Barach

**Name/Title:** Daniele Barach

**Date:** 04/02/2026